The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care
- 303 Downloads
Goals of work
There is little data on the prevalence of use of dietary supplements in cancer, especially in light of the growing evidence that some dietary supplements can have adverse interactions with conventional cancer treatment. The purpose of this study was to investigate the use of dietary supplements among adult cancer patients in a community hospital comprehensive cancer center.
Patients and methods
A survey of 227 new adult cancer patients presenting for treatment for the first time at Cancer Treatment Centers of America at Midwestern Regional Medical Center, between November 2001 and October 2003. Patients completed the McCune Questionnaire, a validated instrument that captures information on the use of 56 dietary supplements in cancer, at admission to the hospital.
Of the 227 patients, 73% used some form of dietary supplements during the 30 day period before the survey was conducted. Dietary supplement use was significantly higher (p = 0.04) in patients with colorectal (80%) and breast (75%) cancer as compared to patients with lung cancer (53%). Patients with stage II (86%) and III (76%) disease at diagnosis were more likely (p = 0.02) to use dietary supplements as compared to those with stage I (71%) disease at diagnosis, while those with stage IV (61%) disease at diagnosis were least likely to use them. Of the 80 patients who had received chemotherapy within the last 30 days, 71% had also used dietary supplements in that timeframe and 25% had consumed one or more herbal therapies that are suspected to have adverse interactions with chemotherapy. Of the 57 patients combining chemotherapy with dietary supplements, 52.6% did not consult a healthcare professional.
In our study, twenty-five percent of patients receiving chemotherapy were concurrently using dietary supplements suspected to have adverse interactions with chemotherapy, usually relying on information sources other than healthcare professionals. Given the prevalence rates of these agents, healthcare providers should systematically inquire about them, and consider the potential for drug-dietary supplement interactions in treatment planning.
KeywordsDietary supplements Cancer Chemotherapy Interaction
We thank Thom Wodek for his contributions in the coordination and daily operation of the study. We also thank Ashmer Aslam for his assistance with data acquisition, database management, and data analysis.
Dr. Gupta and Dr. Grutsch had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis.
This study was funded by Cancer Treatment Centers of America (CTCA). Design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript were conducted by the authors of this study, who take responsibility for its content.
- 1.Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL (1993) Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 328:246–252Google Scholar
- 2.Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M et al (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575Google Scholar
- 3.Markman M (2002) Safety issues in using complementary and alternative medicine. J Clin Oncol 20:39S–41SGoogle Scholar
- 4.Sparreboom A, Cox MC, Acharya MR, Figg WD (2004) Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22:2489–2503Google Scholar
- 5.Fugh-Berman A (2000) Herb–drug interactions. Lancet 355:134–138Google Scholar
- 6.McCune JS, Hatfield AJ, Blackburn AA, Leith PO, Livingston RB, Ellis GK (2004) Potential of chemotherapy–herb interactions in adult cancer patients. Support Care Cancer 12:454–462Google Scholar
- 7.Ashikaga T, Bosompra K, O’Brien P, Nelson L (2002) Use of complimentary and alternative medicine by breast cancer patients: prevalence, patterns and communication with physicians. Support Care Cancer 10:542–548Google Scholar
- 8.Boon H, Westlake K, Stewart M, Gray R, Fleshner N, Gavin A et al (2003) Use of complementary/alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics. Urology 62:849–853Google Scholar
- 9.Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733–1739Google Scholar
- 10.Chrystal K, Allan S, Forgeson G, Isaacs R (2003) The use of complementary/alternative medicine by cancer patients in a New Zealand regional cancer treatment centre. N Z Med J 116:U296Google Scholar
- 11.Cui Y, Shu XO, Gao Y, Wen W, Ruan ZX, Jin F et al (2004) Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res Treat 85:263–270Google Scholar
- 12.DiGianni LM, Garber JE, Winer EP (2002) Complementary and alternative medicine use among women with breast cancer. J Clin Oncol 20:34S–38SGoogle Scholar
- 13.Downer SM, Cody MM, McCluskey P, Wilson PD, Arnott SJ, Lister TA et al (1994) Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 309:86–89Google Scholar
- 14.Nam RK, Fleshner N, Rakovitch E, Klotz L, Trachtenberg J, Choo R et al (1999) Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol 161:1521–1524Google Scholar
- 15.Paltiel O, Avitzour M, Peretz T, Cherny N, Kaduri L, Pfeffer RM et al (2001) Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol 19:2439–2448Google Scholar
- 16.Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514Google Scholar
- 17.Shen J, Andersen R, Albert PS, Wenger N, Glaspy J, Cole M et al (2002) Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med 2:8Google Scholar
- 18.Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB et al (2000) Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18:2515–2521Google Scholar
- 19.Oneschuk D, Fennell L, Hanson J, Bruera E (1998) The use of complementary medications by cancer patients attending an outpatient pain and symptom clinic. J Palliat Care 14:21–26Google Scholar